Supply of products by Bristol-Myers Squibb Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted by the Australian Parliament to regulate the supply of therapeutic goods within Australia. This Act aims to ensure that therapeutic goods are of acceptable quality, safety, and efficacy, and that their benefits outweigh any risks. In 2013, the delegate of the Secretary of the Department of Health and Ageing, under the authority of the Act, issued a notice allowing the supply of certain products by Bristol-Myers Squibb Australia Pty Ltd, despite the products not conforming to the Therapeutic Goods Order (TGO) 69 due to outdated sponsor address details on the labels. The consent granted is conditional, applying until the end of December 2013, and mandates the forwarding of consumer queries or complaints to the new sponsor address. The notice underscores the legislative intent to maintain public safety and ensure the accuracy of information provided on therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989, as applied through Section 14 and 14A, encompasses the regulation and administration of therapeutic goods in Australia. This legislation applies to entities such as Bristol-Myers Squibb Australia Pty Ltd, which is responsible for the supply and distribution of listed therapeutic goods. The Act extends its jurisdiction across the Commonwealth, ensuring uniformity in the regulation of therapeutic goods nationwide. Specifically, the Act authorises the Secretary of the Department of Health and Ageing to give consent for the supply of therapeutic goods that do not conform to certain regulatory standards, such as outdated sponsor address details on product labels, under particular conditions. This consent applies only to the products listed and is effective until the end of December 2013, with the condition that no other changes are made to the products. The consent also requires that any consumer queries or complaints are promptly forwarded to the new sponsor address. The Act allows for the application to be extended or restricted through subordinate instruments, providing flexibility in regulatory enforcement.

Key Provisions

Section 14 of the Therapeutic Goods Act 1989 allows the delegate of the Secretary of the Department of Health and Ageing to consent to the supply of therapeutic goods that do not fully comply with the regulations, subject to certain conditions. In this case, the delegate has consented to the supply of specific products by Bristol-Myers Squibb Australia Pty Ltd until the end of December 2013. The consent pertains to products with labels that still bear the old sponsor address instead of the updated one. The products affected include various pharmaceutical drugs such as aripiprazole (ABILIFY), aztreonam (AZACTAM), entecavir monohydrate (BARACLUDE), and several others listed in the table. The consent is conditional upon the labels remaining unchanged except for the address details, and the company must ensure that any consumer queries or complaints are redirected to the new address. The Therapeutic Goods Act 1989 imposes several obligations on the entities it governs. For Bristol-Myers Squibb Australia Pty Ltd, the primary obligations include adhering to the conditions specified in the consent. This means continuing to supply the listed products until the end of December 2013, ensuring that the labels bear the correct address details, and setting up arrangements to promptly forward any consumer queries or complaints to the new address. Additionally, the company must maintain the integrity of the products as listed, with no other changes permitted to the product specifications or packaging. Failure to comply with the conditions outlined in the consent, or any other provisions of the Therapeutic Goods Act 1989, may result in legal consequences. Offences under the Act can lead to both civil and criminal penalties. For instance, supplying therapeutic goods that do not comply with the regulations could result in fines, imprisonment, or both, depending on the severity and intent of the breach. The maximum penalties for such offences can be significant, reflecting the importance of adhering to the regulatory framework designed to protect public health and safety.